Clinical Trials Logo

Clinical Trial Summary

The objectives of this study are to evaluate the safety and tolerability of a single and multiple oral dose of ASP3325 and to evaluate the effect of administration timing on the pharmacodynamics of ASP3325 orally administered three times a day.


Clinical Trial Description

<Part 1: Single ascending dose> Primary objective

- To evaluate the safety and tolerability of a single oral dose of ASP3325 in non-elderly, healthy adult Japanese male and female, and Caucasian male subjects

Secondary objectives

- To evaluate the pharmacokinetics and pharmacodynamics

- To evaluate gender differences in the pharmacokinetics and pharmacodynamics

- To evaluate ethnic differences in the pharmacokinetics and pharmacodynamics between Japanese and Caucasians

<Part 2: Multiple ascending dose> Primary objective

- To evaluate the safety and tolerability of multiple oral doses of ASP3325 in non-elderly, healthy adult Japanese male and female subjects

Secondary objectives

- To evaluate the pharmacokinetics and pharmacodynamics

- To evaluate gender differences in the pharmacokinetics and pharmacodynamics

<Part 3: Evaluation of the effect of administration timing> Primary objective

- To evaluate the effect of administration timing on the pharmacodynamics of ASP3325 orally administered three times a day at different administration timings of 30 minutes before a meal, during a meal, 30 minutes after a meal, and 2 hours after a meal in non-elderly, healthy adult Japanese male subjects in a crossover design

Secondary objective

- To evaluate the safety and pharmacokinetics ;


Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)


Related Conditions & MeSH terms

  • Pharmacokinetics of ASP3325 in Non-elderly, Healthy Adult Japanese Male and Female, and Caucasian Male Subjects

NCT number NCT02500953
Study type Interventional
Source Astellas Pharma Inc
Contact
Status Completed
Phase Phase 1
Start date July 2013
Completion date December 2013